BRPI0618450A2 - método, bem como uso de pelo menos um polimorfismo, para a determinação e avaliação do risco de um sujeito desenvolver sìdrome coronariana aguda, sondas e/ou iniciadores nucleotìdicos, microarranjo de ácidos nucléicos e de anticorpos, método para a triagem de compostos, bem como para avaliação de possìvel sensibilidade de um sujeito, kit e uso de um agente capaz de modular a atividade de mmp12 - Google Patents

método, bem como uso de pelo menos um polimorfismo, para a determinação e avaliação do risco de um sujeito desenvolver sìdrome coronariana aguda, sondas e/ou iniciadores nucleotìdicos, microarranjo de ácidos nucléicos e de anticorpos, método para a triagem de compostos, bem como para avaliação de possìvel sensibilidade de um sujeito, kit e uso de um agente capaz de modular a atividade de mmp12 Download PDF

Info

Publication number
BRPI0618450A2
BRPI0618450A2 BRPI0618450-2A BRPI0618450A BRPI0618450A2 BR PI0618450 A2 BRPI0618450 A2 BR PI0618450A2 BR PI0618450 A BRPI0618450 A BR PI0618450A BR PI0618450 A2 BRPI0618450 A2 BR PI0618450A2
Authority
BR
Brazil
Prior art keywords
subject
risk
acute coronary
coronary syndrome
polymorphism
Prior art date
Application number
BRPI0618450-2A
Other languages
English (en)
Inventor
Robert Peter Young
Original Assignee
Synergenz Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergenz Bioscience Ltd filed Critical Synergenz Bioscience Ltd
Publication of BRPI0618450A2 publication Critical patent/BRPI0618450A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MéTODO, BEM COMO USO DE PELO MENOS UM POLIMORFISMO, PARA A DETERMINAçãO E AVALIAçãO DO RISCO DE UM SUJEITO DESENVOLVER SìNDROME CORONARIANA AGUDA, SONDAS E/OU INICIADORES NUCLEOTìDICOS, MICROARRANJO DE áCIDOS NUCLéICOS E DE ANTICORPOS, MéTODO PARA A TRIAGEM DE COMPOSTOS, BEM COMO PARA AVALIAçãO DE POSSìVEL SENSIBILIDADE DE UM SUJEITO, KIT E USO DE UM AGENTE CAPAZ DE MODULAR A ATIVIDADE DE MMP1 2. A presente invenção refere-se a métodos para a avaliação do risco de desenvolver síndrome coronariana aguda (ACS) em fumantes e não fumantes, usando a análise de polimorfismos genéticos. A presente invenção também refere-se ao uso de polimorfismos genéticos na avaliação do risco de um sujeito desenvolver ACS. Sondas e iniciadores nucleotídicos, kits e microarranjos adequados para essa avaliação também são apresentados.
BRPI0618450-2A 2005-11-10 2006-11-10 método, bem como uso de pelo menos um polimorfismo, para a determinação e avaliação do risco de um sujeito desenvolver sìdrome coronariana aguda, sondas e/ou iniciadores nucleotìdicos, microarranjo de ácidos nucléicos e de anticorpos, método para a triagem de compostos, bem como para avaliação de possìvel sensibilidade de um sujeito, kit e uso de um agente capaz de modular a atividade de mmp12 BRPI0618450A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ54352005 2005-11-10
NZ54398505 2005-12-06
NZ54995106 2006-09-15
PCT/NZ2006/000292 WO2007055602A1 (en) 2005-11-10 2006-11-10 Methods and compositions for the assessment of cardiovascular function and disorders

Publications (1)

Publication Number Publication Date
BRPI0618450A2 true BRPI0618450A2 (pt) 2011-08-30

Family

ID=38023503

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618450-2A BRPI0618450A2 (pt) 2005-11-10 2006-11-10 método, bem como uso de pelo menos um polimorfismo, para a determinação e avaliação do risco de um sujeito desenvolver sìdrome coronariana aguda, sondas e/ou iniciadores nucleotìdicos, microarranjo de ácidos nucléicos e de anticorpos, método para a triagem de compostos, bem como para avaliação de possìvel sensibilidade de um sujeito, kit e uso de um agente capaz de modular a atividade de mmp12

Country Status (8)

Country Link
US (1) US20100267025A1 (pt)
EP (1) EP1951902A4 (pt)
JP (1) JP2010525788A (pt)
KR (1) KR20080084806A (pt)
AU (1) AU2006312411A1 (pt)
BR (1) BRPI0618450A2 (pt)
CA (1) CA2629388A1 (pt)
WO (1) WO2007055602A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8027791B2 (en) 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
JP5656209B2 (ja) * 2008-09-26 2015-01-21 独立行政法人産業技術総合研究所 ウシタイレリア症の病態評価を可能とする方法
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2019122340A1 (en) * 2017-12-22 2019-06-27 Université D'aix-Marseille In vitro method for predicting a predisposition to acute coronary syndrome
CN111690733B (zh) * 2020-06-22 2022-08-26 复旦大学附属中山医院 一种激素性股骨头坏死易感基因panel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766042A2 (en) * 2004-05-21 2007-03-28 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with chymase (cma1)
CA2608142A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders

Also Published As

Publication number Publication date
WO2007055602A1 (en) 2007-05-18
CA2629388A1 (en) 2007-05-18
JP2010525788A (ja) 2010-07-29
AU2006312411A1 (en) 2007-05-18
KR20080084806A (ko) 2008-09-19
EP1951902A4 (en) 2009-12-02
US20100267025A1 (en) 2010-10-21
EP1951902A1 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
BRPI0618450A2 (pt) método, bem como uso de pelo menos um polimorfismo, para a determinação e avaliação do risco de um sujeito desenvolver sìdrome coronariana aguda, sondas e/ou iniciadores nucleotìdicos, microarranjo de ácidos nucléicos e de anticorpos, método para a triagem de compostos, bem como para avaliação de possìvel sensibilidade de um sujeito, kit e uso de um agente capaz de modular a atividade de mmp12
Bonin et al. Multicentre validation study of nucleic acids extraction from FFPE tissues
White et al. A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR
Du et al. Preparation of DNA aptamer and development of lateral flow aptasensor combining recombinase polymerase amplification for detection of erythromycin
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
Mitsuhashi et al. Nanopore-based single molecule sequencing of the D4Z4 array responsible for facioscapulohumeral muscular dystrophy
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
DE69938623D1 (de) Microarrays und ihre verwendungen
US20120252020A1 (en) Screening Assay for Bladder Cancer
ATE546550T1 (de) Verfahren zum nachweis von hpv sowie sonden, primer und kits
BRPI0509193B8 (pt) método para diagnosticar doença cervical de alto grau em um paciente, e kit
DE602004026077D1 (de) Erstellung von expressionsprofilen unter verwendung von mikroarrays
Yoo et al. International comparison of enumeration-based quantification of DNA copy-concentration using flow cytometric counting and digital polymerase chain reaction
ATE307903T1 (de) Immunologischer nachweis von rna:dna hybriden auf mikroarrays
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
Sidstedt et al. Accurate digital polymerase chain reaction quantification of challenging samples applying inhibitor-tolerant DNA polymerases
JP2009526524A5 (pt)
WO2011133949A3 (en) Genetic risk analysis in reward deficiency syndrome
Lee et al. Implementation of a multiplex and quantitative proteomics platform for assessing protein lysates using DNA-barcoded antibodies
Kondratyev et al. Prediction of smoking by multiplex bisulfite PCR with long amplicons considering allele-specific effects on DNA methylation
US20150079033A1 (en) Detection of bladder cancer and recurrent bladder cancer
Decruyenaere et al. RNA extraction method impacts quality metrics and sequencing results in formalin-fixed, paraffin-embedded tissue samples
ATE394417T1 (de) Sonde zum nachweis von nukleinsäuren
Jiang et al. DNA-hosted Hoechst dyes: application for label-free fluorescent monitoring of endonuclease activity and inhibition

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]